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ABSTRACT
Increasing evidence has suggested an independent association between periodontitis and a
range of comorbidities, for example cardiovascular disease, type 2 diabetes, rheumatoid
arthritis, osteoporosis, Parkinson’s disease, Alzheimer’s disease, psoriasis, and respiratory
infections. Shared inflammatory pathways are likely to contribute to this association, but
distinct causal mechanisms remain to be defined. Some of these comorbid conditions may
improve by periodontal treatment, and a bidirectional relationship may exist, where, for
example, treatment of diabetes can improve periodontal status. The present article presents
an overview of the evidence linking periodontitis with selected systemic diseases and calls for
increased cooperation between dentists and medical doctors to provide optimal screening,
treatment, and prevention of both periodontitis and its comorbidities.
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Introduction
Periodontitis (PDIS) is a common oral disease, the
manifestations of which accumulate with increasing
age. Often, one gets the impression that PDIS is
generally regarded as a natural, almost inevitable
physiological consequence of the aging process. It is
important to change this outdated perception. The
population and the overall health sector should
understand that PDIS is an inflammatory disease
linked to the individual’s oral microbiota and
immune system [1], and that the patients with
PDIS, independent of age, benefit from periodontal
treatment [2]. As outlined below, a number of other
common medical disorders have inflammatory back-
grounds too, which may, at least in part, explain their
comorbidity with PDIS.
The oral cavity harbors a large amount of bacteria. By
using molecular methods, it is now possible to identify
precisely and rapidly >700 bacterial species that com-
prise the oral microbiome, and over the past 15 years,
68% of oral bacterial species in the mouth have been
cultured [3]. Of further interest is that the oral micro-
biome appears to be individualized, implying that it can
vary quantitatively and qualitatively between indivi-
duals, although there are significant overlaps.
Moreover, there is significant variation in themicrobiota
at different sites of the oral cavity in one person [3,4]. It
is also clear that the oral microbiota changes in relation
to different diseases such as PDIS, caries, root canal
infections, and mucositis [5]. For example, there is an
abundance of anaerobic bacteria in the oral cavity, some
of which commonly associates with PDIS. These include
Porphyromonas gingivalis, Tannerella forsythia, and
Treponema denticola (the three members of the ‘red
complex’). Moreover, several bacterial species associated
with PDIS have been suggested to be involved in the
pathogenesis of a number of systemic diseases [6,7].
In the latest decades, there has been considerable
scientific interest in the connection of PDIS with a
number of medical diseases, several of which also
have a high prevalence in the general population.
Limited or no solid evidence exists for a direct causal
relationship between PDIS and other inflammatory
diseases, and documentation in the form of rando-
mized clinical trials is, however, unlikely ever to be
achieved. For example, randomized trials of effects of
PDIS treatment on the incidence of medical comor-
bidities, for example cardiovascular disease (CVD) or
diabetes mellitus (DM), would require long-term fol-
low-up of an enormous number of patients and be
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limited by treatment blinding issues and ethical reser-
vations by leaving PDIS untreated in the placebo
group. Therefore, health authorities must rely on an
assessment of the accumulated plausibility of a causal
relationship between PDIS and its comorbidities,
which will probably forever remain based on a sum
of indirect evidence.
PDIS and CVD
Atherosclerosis, the major cause of CVD, is an inflam-
matory disease that develops in the large arteries, and is
responsible for ischemic heart disease, stroke, and per-
ipheral artery disease. Atheromatous plaques are
usually asymptomatic until they become unstable with
plaque rupture/erosion and thrombosis that are asso-
ciated with increased inflammatory activity in both the
arterial wall and systemically in the body [8]. As indi-
cated above, the question of whether the relationship
between PDIS and atherothrombosis is causal is diffi-
cult to answer definitively. The present reviewwill focus
on clinical studies addressing this issue while results of
numerous exciting experimental studies supporting the
relationship are beyond the scope of the review.
In the recent Swedish ‘PAROKRANK’ study includ-
ing 805 patients <75 years of age with first-time acute
myocardial infarction (AMI) and 805 matched con-
trols without AMI, clinical dental examination and
panoramic X-rays were conducted on all participants
[9]. PDIS, verified by radiographically rated bone loss,
was more common in patients with AMI than it was in
controls. There was an increased (+49%) risk of AMI
among the PDIS patients. The risk remained signifi-
cantly increased (+28%) after adjustment for co-vari-
ables (smoking, DM, socioeconomic factors). These
findings from the largest and most well-conducted
case-control study to date emphasize that there can
be an independent association between PDIS and AMI
[9], which was supported by another recent study from
Scandinavia [10].
Explanatory models
Numerous other population studies, including different
ethnicities, have shown a connection between PDIS and
CVD, and there is increasing evidence for this connec-
tion [11]. This link may be explained by several, not
mutually exclusive, mechanisms (see Table 1).
Significance of periodontal treatment
As indicated above, there are several options for PDIS
to affect the development of atherosclerosis and its
clinical manifestations. The question is whether per-
iodontal treatment can influence this process. A
recent systematic review with meta-analysis con-
cluded that periodontal treatment improves a number
of surrogate measures for atherosclerosis, including
endothelial dysfunction and lipid parameters, gly-
cated hemoglobin (HbA1c), and biomarkers such as
high sensitive C-reactive protein and interleukin (IL)-
6, especially among those who already suffer from
coronary heart disease and DM [21]. A longitudinal
study from the United States has also shown that
improvement of the periodontal status with reduced
clinical probing depth and diminished subgingival
presence of bacteria associated with PDIS among
420 participants resulted in a reduced progression of
carotid intima-media thickness (IMT) over 3 years,
and the average progression of carotid IMT was
Table 1. Explanatory models for association of PDIS and CVD
Transfer of periodontal bacteria to
atheromatous plaques
In subjects with periodontal inflammation, daily oral activities, including chewing and oral hygiene
procedures, may result in transfer of periodontal bacteria from the inflamed pockets to the
bloodstream [12]. A following infection of atherosclerotic arterial walls may result in instability of
plaques with rupture and thrombus formation [13,14]. Studies have demonstrated the presence of
DNA from oral bacteria in atheromatous plaques [15], and some studies using advanced cultivation
techniques have also shown viable periodontal bacteria in the plaques [6,16].
Spillover of cytokines from periodontal tissues
to the bloodstream
Inflammation in the periodontal tissues involves local production of proinflammatory cytokines [17].
Spillover of such cytokines and cytokine producing cells to the bloodstream may enhance
inflammation in the atherosclerotic arterial walls and result in unstable plaques. Thus, elevated levels
of some proinflammatory cytokines, including interleukin (IL)-6 and tumor necrosis factor alpha, have
been found in the bloodstream of patients with PDIS, and PDIS may thus cause systemic low-grade
inflammation [18–21] promoting, for example, endothelial dysfunction and development of insulin
resistance.
Systemic production of cytokines Increased plasma level of cytokines in response to bacteremia after oral procedures is a well-described
phenomenon. For example, increased IL-6 levels were found in the bloodstream as a result of
bacteremia after scaling [22], and this cytokine is a known risk marker for CVD, including AMI [23,24].
Change of lipid metabolism as a result of
PDIS
In patients with PDIS, the lipid balance in the bloodstream, disturbance of which is associated with
increased risk of atherosclerotic disease, shows an unfavorable shift with less high-density lipoprotein
and more low-density lipoprotein cholesterol [25,26]. In addition, studies have indicated
improvement of lipid parameters after periodontal treatment [21].
Endothelial dysfunction PDIS is associated with endothelial dysfunction, which is considered the earliest marker of
atherosclerosis [27]. Furthermore, periodontal treatment may improve endothelial function [28].
Shared genetic risk factors Obviously, there may be unknown shared risk factors of importance, including the genetic profile of
patients with the two diseases. For example, a shared variant in the IL-1 gene complex could be part
of the background for the simultaneous occurrence of both diseases, and recent studies have
identified a number of other shared genetic risk factors [29,30]. However, these factors do not appear
to explain the observed association fully.
PDIS, periodontitis; CVD, cardiovascular disease; AMI, acute myocardial infarction.
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inversely correlated with the improvement of period-
ontal status [31]. According to the authors, the study
emphasized the significance of periodontal treatment
as a possible preventive health effort. As mentioned
above, endothelial dysfunction and carotid IMT are
surrogate measures for atherosclerosis. While the
importance of periodontal treatment for reduction
of clinical cardiovascular endpoints has been sug-
gested in epidemiological studies, for ethical reasons,
randomized trials are unlikely to be performed in this
area of research.
A comprehensive longitudinal study in Taiwan
with an average follow-up period of 7 years was
based on a random sample of one million people
[32]. It was attended by 10,887 people, who had
received dental treatment during the study period.
A total of 10,989 age-, sex-, and comorbidity-matched
subjects who had not received dental treatment were
also included. In the scaling group, a significantly
lower incidence of AMI (1.6% vs. 2.2%; p < 0.001)
and stroke (8.9% vs. 10%; p = 0.03) was seen. A
multivariate analysis showed that scaling was inde-
pendently associated with significantly reduced risk
of AMI (hazard ratio [HR] = 0.69) and stroke
(HR = 0.85). Furthermore, there was a dose-depen-
dent correlation with increased frequency of scaling
leading to greater reduction in the risk of AMI and
stroke. A weakness of this study was, however, that
correction for all known risk factors such as smoking
was not performed [32]. In a recent longitudinal
study, also from Taiwan, 13,573 patients were treated
for mild PDIS in the period 2001–2010, and an equal
number of matched patients were treated for severe
PDIS [33]. Among the latter patients, those who were
>60 years of age had more frequent cardiovascular
events, suggesting that the severity of PDIS plays a
role in these events.
Hypertension
Hypertension is associated with PDIS [34,35], and these
conditions occur frequently in patients with greater
attachment loss [36]. Since hypertension is a treatable
risk factor for CVD, it is important to identify patients
with hypertension. Therefore, it should be considered
whether dentists can contribute to such screening, since
patients usually visit dentists more frequently than they
visit medical doctors for preventive healthcare mea-
sures in the absence of known disease. Sublingual
varices are associated with hypertension [37], and this
oral manifestation may be used as indicator for screen-
ing and referral of patients to their general physician.
Moreover, for the dentist, it is also important to know if
the patient has hypertension, which may contribute to
increased bleeding during oral surgery. In addition,
many patients with hypertension are treated with cal-
cium antagonists that occasionally can cause gingival
hyperplasia, which again may result in increased pro-
gression of PDIS [38]. Obviously, it is up to the dentist
to disrupt this potentially vicious circle.
PDIS and type 2 diabetes
It is well known that there is a relationship between
DM and PDIS. As a result of the obesity epidemic,
there has been a significant growth in the number of
patients with type 2 diabetes (T2D) [39], and it is
expected that dentists will receive increasing numbers
of such patients for diagnosis and treatment in the
future. The relationship is bidirectional in that DM
predisposes for PDIS [40], and PDIS can worsen the
course of DM, as recently reviewed [41].
Explanatory models
There are several ways by which PDIS and T2D may
interfere with each other. DM can affect the develop-
ment of PDIS through a change in the oral micro-
biota, although it is still uncertain whether such a
change actually takes place [42]. The main factor for
the increased propensity to develop PDIS among
diabetics is probably the formation of advanced gly-
cation end products (AGE) by glycation of proteins
and lipids [43]. At high blood-sugar levels, character-
istic of poorly controlled DM, the formation of AGE
is increased, and the receptors for AGE (RAGE) are
also upregulated, which leads to increased production
of proinflammatory cytokines and increased tissue
degradation, including increased bone resorption
and decreased bone formation [44,45]. In addition,
there are studies suggesting that DM patients display
altered function of neutrophils, which play a major
role in the pathogenesis of PDIS [46]. It is important
to emphasize that well-controlled DM patients are
not at increased risk of PDIS. It is thus important
for the dentist to have information about blood-sugar
control in the individual DM patient. On the other
hand, epidemiological studies have linked PDIS to
insulin resistance, and PDIS appears to be an inde-
pendent risk factor for T2D [47,48].
Undiagnosed diabetes
Not all patients with T2D are aware that they have the
disease because the initial symptoms are mild, and
probably almost half of these patients are undiagnosed.
Because it is critical for prevention of DM complica-
tions, including eye disease, kidney disease, neuropa-
thy, and CVD, DM must be diagnosed as early as
possible, and from an individual as well as societal
and economic perspective, it is very unfortunate if
diagnosis is delayed. It is also disadvantageous for
dental treatment that the diabetic state is unknown.
In the above-mentioned Swedish PAROKRANK study
JOURNAL OF ORAL MICROBIOLOGY 3
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[9], in which patients with a first AMI were compared
to controls without ischemic heart disease, glucose
metabolism was examined by oral glucose tolerance
test, and 9.3% of patients with AMI and 5.2% of the
control group had undiagnosed DM. Another recent
study revealed that 3.1% of 291 patients without diag-
nosed T2D who sought dental treatment at the
Department of Odontology at the University of
Copenhagen had HbA1c above the threshold for
T2D, and similarly 27.1% had HbA1c above the
threshold for pre-diabetes [49]. Pre-diabetes is a con-
dition where blood-glucose levels are above the nor-
mal, but still do not qualify for the T2D diagnosis. This
condition, which is a precursor of manifest T2D, is
also known as impaired glucose tolerance. Patients
with PDIS more frequently had elevated HbA1c than
the control group without PDIS did. It is easy and
cheap to implement screening for elevated HbA1c, and
since many patients visit the dentist more regularly
than they do the medical doctor, irrespective of
whether they feel healthy, there is a golden opportu-
nity to implement HbA1c screening in selected risk
patients in dental clinics, with referral to their general
physician in the case of elevated values.
Significance of periodontal treatment
Studies on the significance of periodontal treatment
for the course of T2D often carry considerable meth-
odological limitations, for example missing sufficient
confounder control and with incomplete information
on the efficacy of the periodontal treatment.
However, several meta-analyses have shown that
non-surgical periodontal treatment reduces HbA1c
levels significantly in the range of 0.31–0.65%
[50,51]. Even such small reductions in HbA1c can
be clinically important. Thus, a large British study
demonstrated that every percentage point decrease
in HbA1c may result in as much as 35% reduction
of microvascular complications, and an average
reduction in HbA1c of 0.2% was related to a 10%
lower mortality rate [52]. Therefore, the reduction by
0.31–0.65%, which can be achieved by periodontal
treatment, can have a great impact in terms of sys-
temic health and societal economy.
PDIS and rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease
affecting 0.5–1% of the population in the Western
world. The disease involves inflammation of the
joints, with cartilage degradation and joint deformity,
swelling, and pain [53]. Like PDIS, RA is a chronic
inflammatory condition, which leads to tissue degra-
dation, and an association between the two diseases
has been demonstrated, as recently reviewed [54].
Despite a limited number of participants, the
available studies suggest that both younger and
older patients with RA have an increased predisposi-
tion to attachment loss [55–58]. This might argue for
establishing periodontal prevention programs as part
of routine treatment of patients with RA [55–58].
Explanatory models
PDIS and RA may associate bidirectionally. Both
diseases display elevated circulating and target tissue
levels of markers of inflammation and cytokine pro-
files of ‘tissue degrading’ nature, including increased
production of IL-1 and tumor necrosis factor alpha
(TNF-α) [55–59]. RA is furthermore characterized by
the formation of autoantibodies, including rheuma-
toid factors recognizing immunoglobulin G (IgG)
and antibodies to citrullinated proteins (ACPAs)
[60]. The latter are found in approximately three-
quarters of RA patients, which also have a character-
istic expression of major histocompability complex
molecules capable of binding citrullinated peptides
[61]. Indeed, the subgroups of RA patients who
show immune responses to citrullinated proteins
and those who do not are considered by many inves-
tigators to be two distinct disease entities. Post-trans-
lational conversion of the amino acid arginine to
citrulline is catalyzed by enzymes of the peptidylargi-
nine deiminase (PAD) family, and these are consid-
ered important in disease progression, at least in
ACPA-positive RA [60].
Patients with antibodies against citrullinated pro-
teins more frequently appear to have PDIS than
patients with osteoarthritis do [62]. In addition, RA
patients more frequently have antibodies against
Porphyromonas gingivalis than healthy controls do
[63]. In search for a mechanistic link between PDIS
and RA, special attention has been drawn to P. gingi-
valis, which is the only bacterium with capacity to
produce a PAD (PPAD). Like the corresponding
human enzyme, PPAD is capable of converting argi-
nine to citrulline [64]. In theory, PPAD may therefore
convert harmless host proteins into citrullinated
autoantigens that become the target for autoantibo-
dies and pathogenic T cells that drive RA. Smoking,
which increases the risk of PDIS, is also the strongest
life-style factor linked to the development of RA.
Smoking is also believed to promote the secretion of
PAD from leukocytes in the lungs and thus initiate
citrullination [65].
Significance of periodontal treatment
Several studies have evaluated the effect of period-
ontal treatment on RA and biomarkers of the disease
[58]. The available studies, however, are small and
with limited follow-up, but they suggest that non-
surgical periodontal treatment may reduce clinical
4 P. HOLMSTRUP ET AL.
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symptoms and biomarkers of active RA. Major
intervention studies in RA patients with PDIS are
needed in order to draw firm conclusions on this
matter.
PDIS and osteoporosis
A possible association between PDIS and osteoporosis
was described already in 1968 [66]. Osteoporosis is a
systemic skeletal disease characterized by reduced bone
density. Clinically, osteoporosis is divided into (1) an
idiopathic form that appears early in life and affects
men and women with equal frequency, and (2) an
involutional form, which is subdivided into two types,
the first of which includes postmenopausal women, and
the other being age-related and including both elder
men and women [67]. The most prevalent form is
postmenopausal osteoporosis, the possible association
of which with PDIS has been examined in several
clinical studies. The majority of these studies have
been cross-sectional and with few participants, all post-
menopausal women [68–75]. A recent cross-sectional
study from Taiwan including 35,127 osteoporosis
patients and 50,498 healthy controls showed that PDIS
was associated with an increased risk of osteoporosis
(odds ratio [OR] = 1.29) after adjustment for sex, age,
and comorbidity, and that the risk increased with
increased degree of periodontal inflammation [76].
Furthermore, osteoporosis was associated with a sixfold
increased risk of concurrent PDIS. These results are
supported by a second cross-sectional study from
South Korea, which showed a positive correlation
between PDIS and osteoporosis (OR = 1.21) after
adjustment for age [77]. However, longitudinal studies
are missing to substantiate a causal relationship between
PDIS and osteoporosis.
Explanatory models
Various systemic risk factors, such as genetics, age,
sex, vitamin D deficiency, medical hormone therapy,
diet, smoking, obesity, and physical activity, affects
the development of osteoporosis [78,79], but several
of these are also risk factors for PDIS [80]. Bone
density changes throughout life, but after the meno-
pause a decrease in estrogen production occurs,
which seems to be associated with an increased risk
of osteoporosis. Decreased bone density in the jaw
bone in subjects with osteoporosis is obviously com-
patible with this condition, leading to attachment loss
in individuals with PDIS [72,73,81,82]. Besides being
associated with decreased bone density, estrogen defi-
ciency also affects the other periodontal tissues and
the immune response against the periodontal biofilm
in a proinflammatory direction [81].
Significance of periodontal treatment
As yet, no studies have evaluated the effect of period-
ontal treatment on osteoporosis. Furthermore, it
remains unclear whether bisphosphonate treatment
of postmenopausal patients with osteoporosis wor-
sens or improves periodontal parameters. One
study, however, showed that bisphosphonate therapy
did not reduce alveolar bone loss in osteoporosis
patients with PDIS [82].
PDIS and Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative
disease and the most common example of a group
of diseases causing dementia. It is a progressive
disease, with susceptibility genes working with lit-
tle-understood environmental and behavioral influ-
ences [83]. AD is characterized by atrophy and
neuronal death, especially in the hippocampal
region of the brain [84]. There are two main cate-
gories of AD: the familial, early-onset form that
targets individuals <65 years of age and accounts
for about 2% of all cases of AD; and the late-onset
form of AD that affects older (>65 years) subjects
and accounts for approximately 98% of the cases.
Late-onset AD has several genetic susceptibility
traits. Among these, the apolipoprotein APOE ɛ4
allele is considered to be the most important [85].
The disease is already a great economic burden for
society, and there is currently no treatment. Late
AD probably has several causes, while a genetic
component is more essential for the early form.
Characteristically, late AD includes inflammatory
changes in the brain, which may be initiated by
local or systemic infection [86].
Among the microorganisms most frequently asso-
ciated with AD are bacteria such as spirochetes, P. gingi-
valis, Prevotella, fusobacteria, Actinomyces, and
Chlamydophila pneumoniae. Also, herpes virus
(Epstein–Barr virus and cytomegalovirus) and yeasts of
the genus Candida have been connected with AD [83].
With the exception of C. pneumoniae, all these micro-
organisms can be present in the periodontal pockets.
There is emerging evidence of a link between PDIS
and AD. The relationship has been shown in cross-
sectional and longitudinal studies by examining the
association of AD with clinical signs of PDIS and
circulating levels of antibodies against bacteria asso-
ciated with PDIS, respectively [84].
Explanatory models
Association of AD with periodontal bacteria
In addition to the red complex bacteria, Fusobacterium
nucleatum and Prevotella intermedia, both known to
be associated with PDIS, also associate with AD.
JOURNAL OF ORAL MICROBIOLOGY 5
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Indeed, in the National Health and Nutrition
Examination Survey (NHANES), antibody levels to
these organisms were significantly increased in serum
from patients with AD compared to controls [87]. This
result was significant after controlling for each sub-
ject’s age, Mini-Mental State Examination score, and
APOEԑ4 allele status. Unexpectedly, Noble et al. found
that a high (>640 ng/mL) anti-Actinomyces naeslundii
titer was present in 10% of subjects with increased risk
of AD, suggesting that AD pathogenesis may involve a
spectrum of bacteria [88].
In 14 studies, oral spirochetes that are neuro-
trophic were demonstrated in the brain of AD
patients. Seven different spirochetes were identified
in 14/16 AD brains [89,90]. Spirochetes induced bio-
logical and pathological characteristics of AD (plaque
accumulations of beta-amyloid and neurofibrillary
tangles) after exposure of neuronal and glial cells in
organ cultures. Lipopolysaccharide (LPS) from P.
gingivalis was also detected in human brains with
AD but not in control brains [91]. In a study based
on 2,355 people >60 years of age, a positive correla-
tion between PDIS and cognitive impairment was
found, and a negative correlation was observed
between antibody titers to P. gingivalis and scores in
cognitive tests [87,92].
The original inflammatory hypothesis of AD sug-
gested that AD hallmark proteins, for example beta-
amyloid, were the main contributors to central ner-
vous system inflammation. This hypothesis has been
expanded to include involvement of infections, and
life-style, genetic, and environmental factors in AD
pathogenesis. PDIS is a prototypical oral condition
that encompasses all these factors, including patho-
genic bacteria [93].
Microorganisms and inflammatory mediators
may reach the brain
Oral microorganisms and inflammatory mediators can
be transported from inflamed periodontal tissues to the
brain via the bloodstream. An increased amount of
cytokines, particularly the macrophage-secreted TNF-
α, has been detected in the plasma of AD subjects [94].
Also, elderly people harbored a higher titer of circulat-
ing IgG against several periodontal pathogens [87].
Cestari et al. [95] found an association between circu-
lating IL-6 and TNF-α levels in patients with AD and
PDIS, implicating these proinflammatory cytokines in
the overlapping pathogenic mechanisms between oral
infections and AD [95].
As mentioned above, daily episodes of bacteremia
follow from dental procedures, including toothbrush-
ing and flossing, and from chewing, particularly in
patients with PDIS. The bacteria involved can disse-
minate into the brain by closely related anatomical
pathways, that is, trigeminal and olfactorial nerves
[93]. The long-term effect of inflammatory mediators
and pathogens and/or their virulence factors reaching
the brain may over time prime the brain’s own
microglia in individuals having inherent susceptibility
traits. According to Singhrao et al., such susceptibil-
ities could contribute to inadequate neutralization of
invading agents reaching the brain and result in loss
of cytoarchitectural integrity and vital neurons with
subsequent deterioration of cognitive function [93].
Blood–brain barrier
The permeability of the blood–brain barrier (BBB)
increases with age. Prolonged exposure to high con-
centrations of TNF-α tends to weaken the protective
role of the BBB, making it more permeable to bac-
teria or endotoxins [96]. The APOE ԑ4 gene is also
associated with increased BBB permeability, allowing
microorganisms, their products, and inflammatory
mediators such as TNF-α to penetrate into the brain
[97]. These microorganisms and substances can also
pass through circumventricular tissues and perivas-
cular spaces of the brain because these regions lack a
BBB [98]. The olfactory nerve and the trigeminal
nerve also circumvent the BBB [99]. Indeed, olfactory
cells may act as Trojan horses by which microorgan-
isms can reach the brain [100].
Bacteria in the brain
Biofilm has been demonstrated in the brain of AD
patients and was probably created by dental and Lyme
spirochetes with accompanying local tissue activation of
the innate immune system [101]. Riviere et al. also
demonstrated the presence of seven different
Treponema species in 14/16 specimens from AD brains
[102].Microorganisms and their toxic products as well as
microbial DNA have been reported in the brain tissue of
AD patients and animal models [83]. Spirochetes induce
a latent and slowly progressive infection by circumvent-
ing host defense, and are able to induce beta-amyloid
plaque formation in the brain [87,92]. Periodontal bac-
teria, especially T. denticola, may contribute to AD
pathology using a range of inflammatory mechanisms
by which neurons would be attacked. This occurs despite
the fact that these bacteria inhibit inflammasome activity
[103,104]. Spirochetes possibly promote their own survi-
val and proliferation by blocking the complement cas-
cade [105]. Moreover, P. gingivalis has LPS with various
lipid A structures and is capable of modifying the latter
components, which may provide the bacteria with the
capacity to disguise itself from recognition by the
immune system via TLR4 [106].
Genetics, environmental factors, nutrition, and
other factors
A very important risk factor for AD is the APOE ԑ4
gene, which is associated with susceptibility for
6 P. HOLMSTRUP ET AL.
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infections and increases the expression of inflamma-
tory mediators [107]. In total, 20 different genetic loci
have been estimated to increase the susceptibility to
AD, including APOE ԑ4. These include the genes for
IL-1β and TNF-α, which are also linked to the devel-
opment of PDIS [108]. The pathogenesis of AD prob-
ably includes an interaction between genes,
microorganisms/toxins, and environmental factors.
Inadequate nutrient intake is common in the elderly
and in people with dementia, and this can contribute
to gradual loss of nerve synapses. In addition, neglect
of or an inability to maintain oral hygiene in the
elderly promotes inflammation in the periodontium,
which may favor the transport of microorganisms
and their products, as well as inflammatory media-
tors, to the brain. Loss of teeth, which is often the
result of PDIS, has been connected to a poor mem-
ory [109].
PDIS and Parkinson’s disease
Parkinson’s disease is another chronic neurodegen-
erative disease that results in selective loss of dopa-
minergic neurons in the substantia nigra of the brain.
During the progression of Parkinson’s disease, there
is a gradual degeneration of the nigrostriatal com-
pounds, leading to cognitive, motor, and psychiatric
symptoms. There is still no solid evidence that PDIS
influences the pathogenesis of Parkinson’s disease
[110]. However, there are studies indicating that
PDIS is more common in patients with Parkinson’s
disease, although large longitudinal studies and ran-
domized case-control or case-cohort studies are lack-
ing to substantiate this association [111,112].
Explanatory models
Parkinson’s disease causes motor disability, which
complicates the provision of simple daily oral proce-
dures such as brushing the tooth, which will inevita-
bly lead to the accumulation of plaque. In addition,
the cognitive changes in patients with Parkinson’s
disease may have an impact on the quality and fre-
quency of the home dental-care habits (as well as the
dentists’ willingness to perform periodontal treat-
ment), which contributes to increased plaque accu-
mulation and risk of PDIS. A number of studies also
indicate that systemic low-grade inflammation
induced by PDIS [17,19,22] contributes to neural
dysfunction at early stages of Parkinson’s disease
[110]. Much evidence suggests that the pathogenesis
of Parkinson’s disease has an inflammatory compo-
nent, for example elevated plasma IL-6 appears to
increase the risk of the disease [113,114]. There are
no published studies on the effect of periodontal
treatment of patients with Parkinson’s disease.
PDIS and psoriasis
Psoriasis is a chronic inflammatory disease with a
prevalence of up to 8.5% of the population in the
Nordic countries. The disease is also characterized by
extensive comorbidity in the form of, for example,
CVD and T2D, probably on the basis of shared
inflammatory mechanisms [115–117]. An association
between psoriasis and chronic PDIS has been shown,
and increased concentrations of proinflammatory
cytokines such as TNF-α and IL-1β have been
found in saliva from patients with psoriasis [118–
120]. The results from a large epidemiological study
from Taiwan also suggest that intensive treatment of
chronic PDIS can reduce the risk of psoriasis [121].
Activated T-helper (Th)-17 cells producing IL-17 are
key pathogenic players in psoriasis, and bacterial
infection, including infection with P. gingivalis, can
promote the polarization of naïve T-helper cells into
Th-17 cells. Also, activated Th-17 cells have been
found in periodontal lesions, and increased IL-17
levels have been demonstrated in crevicular fluid
from patients with MP [122–124].
Lung diseases and oral hygiene
Colonization of the oral cavity with respiratory patho-
gens related to a lack of oral hygiene and PDIS can be
linked to the development of pneumonia. There is
strong scientific evidence from randomized clinical
trials that interventions aimed at improving oral
hygiene may prevent pneumonia and reduce pneumo-
nia-related deaths, particularly in elderly care-depen-
dent patients [125]. A Norwegian study also showed
that chronic PDIS occurs more frequently in patients
with severe chronic obstructive pulmonary disease,
even after adjusting for risk factors such as age, smok-
ing, obesity, corticosteroid use, and decreased bone
density [126].
Conclusion
There are numerous studies showing a correlation
between PDIS and a variety of medical disorders.
This is not surprising, since the mouth, of course, is
part of the human body. These medical conditions
are particularly frequent in the elderly population.
Important for the dental clinician, there is evidence
to suggest that periodontal treatment may have ben-
eficial effects on some of these conditions (Table 2). It
is obvious that cooperation between medical doctors
and dentists should be strengthened, and a major
prerequisite for this is increased awareness and
knowledge about the disease connections mentioned
in this article. Importantly, low-grade inflammation
is considered to be one of the most prominent
JOURNAL OF ORAL MICROBIOLOGY 7
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mechanistic links between PDIS and its medical
comorbidities.
A considerable amount of knowledge has accumu-
lated about the link between PDIS and CVD, with
growing evidence for a causal relationship. There are
plausible mechanistic data (including experimental
results that are not discussed here), and it appears
that periodontal treatment may reduce the risk of
atherosclerotic disease.
There is also extensive evidence that poor blood-
sugar control in patients with T2D leads to an increased
risk of PDIS with increased severity and extension, and
that PDIS may lead to increased risk of elevated HbA1c
and T2D. The growing prevalence of T2D in the popu-
lations will probably result in increased development of
PDIS, which in turn can aggravate the course of T2D.
Thus, the two diseases have a bidirectional relationship,
presumably due to shared immunological reactions.
Clinical studies also indicate that non-surgical period-
ontal treatment can improve metabolic control, which
may reduce the development of diabetic complications.
There are ample reasons for establishing systematic
examination, prevention, and therapy programs for
PDIS in diabetic patients.
Evidence suggests that there is also a bidirectional
link between PDIS and RA, with increased risk for PDIS
in patients with RA, and non-surgical periodontal treat-
ment may reduce clinical symptoms and biomarkers of
active RA. The increased propensity for attachment loss
in patients with RA can also speak for the establishment
of a periodontal prevention program as part of routine
treatment of these patients. Moreover, studies of
patients with osteoporosis suggest that there is an
increased propensity to develop attachment loss.
PDIS is also associated with certain neurological
disorders. Parkinson’s disease involves motor impair-
ment and cognitive changes, which may entail dete-
rioration of home dental-care habits. Moreover, low-
grade inflammation, for example as a result of PDIS,
may contribute to neurological dysfunction in the early
stages of Parkinson’s disease. AD has a complex and
multifactorial etiology, and periodontal infection may
be one of several risk factors for AD. Thus, the presence
of periodontal bacteria and their products have been
found in the brain of AD patients. Infection can occur
decades before AD becomes apparent. Improved oral
hygiene can be an important prophylactic measure, but
unfortunately can be challenging because AD patients
are not always cooperative.
Psoriasis is characterized by widespread comorbidity
in the form of, for example, CVD, diabetes, and PDIS,
which probably also has a background in shared inflam-
matory mechanisms. Finally, there is scientific evidence
that better oral health has a positive effect in the pre-
vention of pneumonia, especially in elderly care-depen-
dent patients.
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